Rare Disease · In-Market · Updated August 2026
Four mechanisms reached this market inside a few years, none of them interchangeable, and the sequence in which they should be used is still unsettled.
IgA nephropathy is diagnosed by biopsy, which gates the funnel before any commercial question is reached. Sizing starts from the high-risk, treatment-eligible cohort rather than from headline prevalence, because the patients who reach a nephrologist and are biopsied are a fraction of those who have the disease.
The four available mechanisms act at different points in the pathology and are not substitutes for one another. Targeted-release budesonide acts on gut-associated production of galactose-deficient IgA1. Endothelin-A blockade targets haemodynamic and fibrotic injury. Complement inhibition addresses a third pathway. A positioning argument built on relative efficacy misses this: the question is which mechanism suits which patient at which point, and that determines sequencing more than any comparative claim does.
Every agent in the wave won accelerated approval on proteinuria reduction rather than on hard renal outcomes. That surrogate shapes both the commercial and the access case. It shortens the path to market and lengthens the confirmatory obligation, and it gives payers a reason to hold agents behind one another until outcome data arrives. First movers hold installed share while later entrants argue for a place in a sequence nobody has agreed.
AXLRx IgA nephropathy reports size the biopsy-gated funnel across the US, UK and Gulf, map the four mechanisms against the patients each actually fits, and model launch-wave dynamics where sequencing rather than share is the contested question. Each report is a sample output of the AXLRx commercial consulting engine, and the same analysis can be commissioned for your asset and market.
For the wider context, see orphan drug approvals in numbers: FDA and EMA orphan approvals counted by year, condition and sponsor.
IgA nephropathy is the most common biopsy-proven primary glomerulonephritis, driven by circulating galactose-deficient IgA1. Adult primary IgAN incidence in a diverse US population runs roughly 1.29 to 2.2 new cases per 100,000 per year, highest in patients of Asian ancestry and lowest in Black patients. Epidemiology-based modeling implies about 150,000 total US patients, yet only 70,000 to 90,000 carry a biopsy-confirmed diagnosis. The diagnosed pool understates true prevalence, so the identification gap is the commercial starting point.
Diagnosis is definitional: primary IgAN is confirmed only by kidney biopsy scored with the Oxford MEST-C system, which also carries prognostic weight. Most patients surface through proteinuria or hematuria on routine testing, then wait for nephrology referral and biopsy before any disease-specific label applies. That biopsy gate is the narrowest point of the funnel, and patients with milder proteinuria are often managed as generic chronic kidney disease and never biopsied. Proteinuria and eGFR then convert a diagnosis into a treatment decision.
Five FDA-approved IgAN-specific therapies now compete across four mechanisms. Targeted-release budesonide (Tarpeyo, Calliditas/Otsuka), a gut-directed corticosteroid, was first, winning accelerated approval in December 2021 and full approval in December 2023. Sparsentan (Filspari, Travere) is a dual endothelin-A and angiotensin receptor antagonist. Iptacopan (Fabhalta, Novartis) inhibits complement factor B; atrasentan (Vanrafia, Novartis) is a selective endothelin-A antagonist approved in April 2025; and sibeprenlimab (Voyxact, Otsuka) is a first-in-class anti-APRIL antibody cleared in November 2025. Four are oral; sibeprenlimab is subcutaneous.
Not every diagnosed patient progresses. Roughly 30 to 40 percent reach end-stage kidney disease over 20 to 30 years, and registry data show a median kidney survival near 11 years, so treating the whole diagnosed pool overstates the opportunity. AXLRx builds a progression-risk funnel that starts from the biopsy-diagnosed base, then filters on the two accepted risk markers, persistent proteinuria above 1 g/g and a declining eGFR slope, layered on optimized ACEi/ARB and SGLT2i background therapy. In the US that logic narrows 70,000 to 90,000 diagnosed patients to a 15,000 to 25,000 high-risk, treatment-eligible cohort. That stratified cohort, not total prevalence, is the pool that governs near-term volume.
Sizing starts from the high-risk treatment-eligible cohort, not headline prevalence, then models launch-wave dynamics. First-mover budesonide and sparsentan hold installed share, while atrasentan, iptacopan and sibeprenlimab compete for the switch and add-on lines that guidelines have not yet fixed. AXLRx layers a share-sequencing model over the risk-stratified funnel, testing order-of-entry, mechanism fit and step-through position against the prior-authorization gate. With only 5,000 to 8,000 US patients on any novel agent today against a 15,000 to 25,000 eligible pool, the real question is capture rate inside a defined, still-under-penetrated cohort. The sizing exercise is a proteinuria-thresholded funnel with a launch-wave share overlay, not a prevalence multiplication.
Every agent won accelerated approval on proteinuria reduction, ranging from about 38 to 51 percent versus comparator: atrasentan cut UPCR 38.1 percent versus 3.1 for placebo, sparsentan 49.8 versus 15.1 for irbesartan, and sibeprenlimab 51.2 percent lower. But payers and HTA bodies increasingly discount the proteinuria surrogate and reward confirmatory eGFR-slope evidence, which so far only budesonide and sparsentan carry. AXLRx models how that endpoint gap shifts value, converting an eGFR-slope benefit into a projected ESKD-delay case that reframes price against dialysis-cost avoidance rather than proteinuria alone. The endpoint a team can prove, not the one it headlines, is what clears the access bar.
The four mechanisms are not interchangeable. Budesonide acts on gut-associated galactose-deficient IgA1 production, endothelin-A blockade (sparsentan, atrasentan) targets hemodynamic and fibrotic injury, complement inhibition (iptacopan) hits the alternative pathway, and anti-APRIL (sibeprenlimab) suppresses the upstream driver. AXLRx maps each mechanism against the risk-stratified funnel and the prior-authorization gate, testing combinability, step-through order and the hepatotoxicity REMS that constrains sparsentan. Positioning is decided by where a mechanism fits in the treatment sequence for a defined high-risk patient, not by headline efficacy in isolation. Sequencing logic, built on the same identification funnel, is the strategy in a crowded four-mechanism market.
Each answer here compresses an AXLRx report built for IgA nephropathy across the US, UK and GCC. A disease-landscape and patient-flow read sizes the biopsy-gated funnel from prevalence down to the high-risk, treatment-eligible cohort. A competitive-intelligence brief compares the five agents on mechanism, accelerated-approval efficacy and confirmatory eGFR evidence. A payer and HTA assessment decodes the prior-authorization gate, the sparsentan REMS and the ESKD-delay value case. The same molecule faces a different funnel, evidence bar and access gate in each geography, and that identification-and-stratification analysis is what a launch team can commission.